With first quarter earnings season drawing to a close, here is a look at the performance of a couple of top-ranked large cap pharma stocks, Merck & Co., Inc.MRK and SanofiSNY, and what lies ahead for the remainder of the year. An In-Depth …
NASDAQ
Sanofi might also settle to protect its reputation among investors ... I have no business relationship with any company whose stock is mentioned in this article. …
Genzyme CVR
Sanofi SA (NYSE:SNY) was upgraded by research analysts at TheStreet from a “c+” rating to a “b-” rating in a research note issued to investors on Monday, April 24th. SNY has been the topic of several other research reports. Goldman …
BNS6d
Sanofi
On the stock market today, Regeneron stock rose 0.1% to 461.37, as Sanofi stock fell 0.2% to 49.07. Shares of rivals Amgen and AbbVie were up 0.7% and 0.6%, …
Rheumatoid Arthritis
Like A Spycam Peeking Into Fidelity Stock Moves, This Info Can Pump Up Your Retirement ... which Regeneron is developing as part of a collaboration with …
Sanofi
stock enjoyed a nice bounce. The biotech announced solid sales for eye-disease drug Eylea and a strong launch for atopic dermatitis drug Dupixent with partner …
Big Bounce
1 analyst given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for SNY is $47.00 while analysts mean …
Sanofi SA
On Friday, May 19, 2017, the stock closed the trading session at $49.31, marginally climbing 0.33% from its previous …
Diabetes mellitus
Sanofi SA (ADR) (NYSE:SNY) has risen 6.00% since April 19 ... The firm presently has an "underperform" rating on the stock. As per Friday, April 29, the company …
Stock Rating Reaffirmed